A Phase 1 interventional study of vorinostat and Comparator: bexarotene in Lymphoma, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing vorinostat in Lymphoma — none open to participants now, 1 under way, 1 of them phase 3. Vorinostat · Lymphoma.
Among the 20 studies testing vorinostat in Lymphoma, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2005, is one of 7 in phase 1, and was the 2nd registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →None of the 20 studies testing vorinostat in Lymphoma is open now. The open studies under Lymphoma, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 2
First in 2000; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 17 across the 19 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
17 studies in Lymphoma by Merck & Co., Inc: 2 open now, 4 under way, none of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 17 studies in Lymphoma by Merck & Co., Inc, this one is the 13th largest by enrollment, is one of 2 that started in 2005, is one of 11 in phase 1, and was the 4th registered.
Merck & Co., Inc’s Lymphoma studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing vorinostat in Lymphoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 17 in Lymphoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients who have failed at least one prior systemic therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter\[2\] daily x 7 days per week
Drug: vorinostat · Drug: Comparator: bexarotene
Vorinostat 300 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter\[2\] daily x 7 days per week
Drug: vorinostat · Drug: Comparator: bexarotene
Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 225 milligrams/meter\[2\] daily x 7 days per week
Drug: vorinostat · Drug: Comparator: bexarotene
Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 300 milligrams/meter\[2\] daily x 7 days per week
Drug: vorinostat · Drug: Comparator: bexarotene
Vorinostat 400 milligrams daily for 7 days per week + Bexarotene 150 milligrams daily for 7 days per week
Drug: vorinostat · Drug: Comparator: bexarotene
Vorinostat 400 milligrams daily for 7 days per week + Bexarotene daily for 7 days per week \[150 milligrams (Cycle 1) 225 milligrams (Cycle 2-6)
Drug: vorinostat · Drug: Comparator: bexarotene
Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.
Also known as: Zolinza
Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
Also known as: Targretin
Maximum Tolerated Dose (MTD) as Determined by the Number of Participants With Dose Limiting Toxicities
Number of patients with Dose Limiting Toxicities (DLT). A DLT is an adverse event that determined the treatment dose level was not tolerable for that patient in Cycle 1.
Time frame: Day 1 to day 28
Number of Participants Who Responded to Treatment
Disease burden as assessed by the pre-specified Severity Weighted Assessment Tool (SWAT) measurement. A Response is defined as equal to or greater than 50% improvement in SWAT score. SWAT Score is determined by the Lesions classified as patch, plaque, or tumor. The sum of percent of total body surface area (%TBSA) by lesion type is derived and multiplied by a factor of 1 (for patch), 2 (for plaque), or 4 (for tumor). The skin score total is derived by summing the skin score subtotals for patches, plaques and tumors. The skin score total is dimensionless and can range from 0 to 400
Time frame: Every 28 days for up to 6 Months of Treatment
| Milestone | Cohort 1 | Cohort 2 | Cohort 2a | Cohort 2b | Cohort 6 | Cohort 7 |
|---|---|---|---|---|---|---|
| Started | 3 | 5 | 3 | 3 | 5 | 4 |
| Completed | 1 | 1 | 1 | 3 | 3 | 3 |
| Not completed | 2 | 4 | 2 | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 | 0 | 0 | 1 |
| Milestone | Cohort 1 | Cohort 2 | Cohort 2a | Cohort 2b | Cohort 6 | Cohort 7 |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 1 | 0 | 3 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 0 | 3 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 2 | 1 |
Number of patients with Dose Limiting Toxicities (DLT). A DLT is an adverse event that determined the treatment dose level was not tolerable for that patient in Cycle 1.
| Participants | Cohort 1 | Cohort 2 | Cohort 2a | Cohort 2b | Cohort 6 | Cohort 7 |
|---|---|---|---|---|---|---|
| DLT | 0 | 2 | 0 | 0 | 0 | 1 |
| No DLT | 3 | 3 | 3 | 3 | 5 | 2 |
Disease burden as assessed by the pre-specified Severity Weighted Assessment Tool (SWAT) measurement. A Response is defined as equal to or greater than 50% improvement in SWAT score. SWAT Score is determined by the Lesions classified as patch, plaque, or tumor. The sum of percent of total body surface area (%TBSA) by lesion type is derived and multiplied by a factor of 1 (for patch), 2 (for plaque), or 4 (for tumor). The skin score total is derived by summing the skin score subtotals for patches, plaques and tumors. The skin score total is dimensionless and can range from 0 to 400
| Participants | Cohort 1 | Cohort 2 | Cohort 2a | Cohort 2b | Cohort 6 | Cohort 7 |
|---|---|---|---|---|---|---|
| Response | 0 | 0 | 0 | 1 | 2 | 1 |
| No Response | 3 | 5 | 3 | 2 | 3 | 2 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | — | — | — |
| Cohort 2 | — | — | — |
| Cohort 2a | — | — | — |
| Cohort 2b | — | — | — |
| Cohort 6 | — | — | — |
| Cohort 7 | — | — | — |
| Event | Cohort 1 | Cohort 2 | Cohort 2a | Cohort 2b | Cohort 6 | Cohort 7 |
|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/3 | 0/5 | 1/3 | 0/3 | 0/5 | 0/4 |
| Lymph Node AbscessInfections and infestations | 1/3 | 0/5 | 0/3 | 0/3 | 0/5 | 0/4 |
| LymphangitisInfections and infestations | 1/3 | 0/5 | 0/3 | 0/3 | 0/5 | 0/4 |
| T-Cell LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/3 | 0/5 | 0/3 | 0/3 | 0/5 | 0/4 |
| Skin NecrosisSkin and subcutaneous tissue disorders | 0/3 | 0/5 | 1/3 | 0/3 | 0/5 | 0/4 |
| GastroenteritisInfections and infestations | 0/3 | 0/5 | 0/3 | 0/3 | 0/5 | 1/4 |
| HypersensitivityImmune system disorders | 0/3 | 1/5 | 0/3 | 0/3 | 0/5 | 0/4 |
| PneumoniaInfections and infestations | 0/3 | 1/5 | 0/3 | 0/3 | 0/5 | 0/4 |
| FallInjury, poisoning and procedural complications | 0/3 | 0/5 | 0/3 | 0/3 | 1/5 | 0/4 |
| Mycosis FungoidesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/5 | 0/3 | 0/3 | 1/5 | 0/4 |
| Event | Cohort 1 | Cohort 2 | Cohort 2a | Cohort 2b | Cohort 6 | Cohort 7 |
|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 0/3 | 2/5 | 0/3 | 0/3 | 5/5 | 1/4 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 3/3 | 3/5 | 2/3 | 1/3 | 1/5 | 2/4 |
| HypothyroidismEndocrine disorders | 2/3 | 3/5 | 1/3 | 2/3 | 1/5 | 3/4 |
| LeukopeniaBlood and lymphatic system disorders | 2/3 | 1/5 | 1/3 | 0/3 | 0/5 | 0/4 |
| LymphopeniaBlood and lymphatic system disorders | 2/3 | 1/5 | 0/3 | 0/3 | 0/5 | 0/4 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 0/3 | 1/5 | 1/3 | 2/3 | 1/5 | 1/4 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 0/3 | 0/5 | 2/3 | 0/3 | 1/5 | 1/4 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 3/5 | 0/3 | 0/3 | 0/5 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 3/5 | 0/3 | 0/3 | 1/5 | 1/4 |
| NauseaGastrointestinal disorders | 0/3 | 1/5 | 0/3 | 0/3 | 3/5 | 2/4 |
| Age, Customized(participants) | Cohort 1 | Cohort 2 | Cohort 2a | Cohort 2b | Cohort 6 | Cohort 7 | Total |
|---|---|---|---|---|---|---|---|
| 26-35 years of age | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| 36-45 years of age | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| 46-55 years of age | 0 | 0 | 1 | 1 | 1 | 1 | 4 |
| 56-65 years of age | 1 | 1 | 1 | 2 | 3 | 1 | 9 |
| 66-75 years of age | 1 | 1 | 0 | 0 | 0 | 2 | 4 |
| Over 75 years of age | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 2a | Cohort 2b | Cohort 6 | Cohort 7 | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 0 | 2 | 2 | 2 | 9 |
| Male | 1 | 4 | 3 | 1 | 3 | 2 | 14 |
| Race/Ethnicity(participants) | Cohort 1 | Cohort 2 | Cohort 2a | Cohort 2b | Cohort 6 | Cohort 7 | Total |
|---|---|---|---|---|---|---|---|
| Turkish | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| White | 3 | 5 | 3 | 2 | 5 | 4 | 22 |
No study locations are listed for this record.
The record gives a start of Sep 2005, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat